Citi launched its coverage of Cytokinetics (NASDAQ:CYTK) with a Buy recommendation, noting that the cardiac drug developer’s recent selloff is overdone given that its lead asset, aficamten, which has ...

Citi initiated coverage of Cytokinetics (CYTK) with a Buy rating and $86 price target. The shares seem attractive at current levels, given the ...

Citi initiated coverage on Cytokinetics (NASDAQ:CYTK) with a Buy rating and an $86.00 price target, representing significant upside from the current price of $46.17. The firm's analysts highlighted ...

JMP Securities analyst Jason Butler maintained a Buy rating on Cytokinetics (CYTK – Research Report) today and set a price target of $78.00.

Cytokinetics (NASDAQ:CYTK – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They presently have ...

SAN FRANCISCO — Cytokinetics CEO Robert Blum is very clear. The company — on track to secure U.S. approval in September for a drug to treat a serious heart condition — is not for sale.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Cytokinetics announced that it has begun enrolling patients in its mid-stage study of CK-4021586 (CK-586), a ...

Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Cytokinetics in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst C ...

The stock options, RSUs and PSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635 (c) (4).

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its seventh annual Communications Grant Program ...